Filing Details
- Accession Number:
- 0001214659-22-011325
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-20 16:30:15
- Reporting Period:
- 2022-09-19
- Accepted Time:
- 2022-09-20 16:30:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1677077 | Alzamend Neuro Inc. | ALZN | Pharmaceutical Preparations (2834) | 811822909 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1864257 | Stephan Jackman | 3500 Lenox Rd Ne, Suite 1500 Atlanta GA 30326 | Chief Executive Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-09-19 | 8,500 | $1.23 | 8,500 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Footnotes
- The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.2252. The range of purchase prices on the transaction date was $1.225 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.